Ditchcarbon
  • Contact
  1. Organizations
  2. Geron Corporation
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 24 days ago

Geron Corporation Sustainability Profile

Company website

Geron Corporation, a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 1990, Geron has made significant strides in the field of telomerase biology, positioning itself as a leader in the development of telomerase inhibitors. The company’s flagship product, imetelstat, is a first-in-class telomerase inhibitor that targets cancer stem cells, offering a unique approach to treating various malignancies. Geron’s commitment to advancing cancer treatment has garnered attention within the industry, as it continues to explore new therapeutic avenues and expand its operational reach. With a strong emphasis on research and development, Geron Corporation remains at the forefront of biopharmaceutical innovation, striving to improve patient outcomes in oncology.

DitchCarbon Score

How does Geron Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Geron Corporation's score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

42%

Let us know if this data was useful to you

Geron Corporation's reported carbon emissions

Geron Corporation, headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The absence of emissions data suggests that the company may not have publicly disclosed its carbon footprint or climate commitments at this time. As a result, there are no specific figures to report regarding Scope 1, 2, or 3 emissions, nor any significant achievements in emissions reduction. Without concrete data, it is unclear how Geron Corporation aligns with industry standards for climate action or whether it has set any science-based targets for emissions reductions. In the context of corporate climate commitments, it is essential for companies like Geron to establish clear goals and transparent reporting to contribute effectively to global climate efforts.

How Carbon Intensive is Geron Corporation's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Geron Corporation's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Geron Corporation's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Geron Corporation is in US, which has a low grid carbon intensity relative to other regions.

Geron Corporation's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Geron Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Geron Corporation's Emissions with Industry Peers

PharmaEssentia USA Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Agios

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

BioMarin

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy